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Reply to J.J. Tosoian et al
Potential overtreatment of prostate cancer has increased the
use of active surveillance (AS).1 We agree with Tosoian and Carter2
that variable inclusion criteria used in previous studies3 and the
lack of mature randomized data mean that there is uncertainty in
identifying the ideal patient population to receive AS. We would
like to conﬁrm that the endorsed Cancer Care Ontario (CCO)
guideline4 applied a quality assessment of the included studies, and
this was taken into consideration during our evaluation. The original
CCO guideline did not include any strength-of-recommendation
ratings, and none were added according to ASCO endorsement
methodology.
For low-risk cancer, there is a lack of compelling evidence
showing that immediate treatment improves overall survival. The
SPCG-4 (Scandinavian Prostate Cancer Group Trial Number 4)
trial5 randomly assigned patients to watchful waiting versus radical
prostatectomy and found a nonsigniﬁcant 3.8% mortality re-
duction for low-risk patients in the prostatectomy group with
a median follow-up of. 13 years. However, it is not clear whether
this difference applies to screening-detected patients, and whether
AS differs from watchful waiting. A more contemporary random-
ized trial showed no survival beneﬁt from radical prostatectomy
versus observation in low-risk patients through at least 12 years of
follow-up.6
We agree that more research is needed to identify the ideal
patient group for AS. The ASCO endorsement acknowledges and
provides qualifying statements regarding patient characteristics
such as age, race, and volume of disease and acknowledges that
treatment decisions should be made in consideration of the in-
dividual patient. To date, there are no data suggesting that any
patient characteristics (including patients classiﬁed as very–low
risk v low risk by the National Comprehensive Cancer Network)
indicate a need for immediate treatment of low-risk patients.
Indeed, recent evidence suggests rates of upgrading and upstaging
were comparable in black and white men with low-risk pros-
tate cancer.7 Two of the largest, most mature AS studies had the
broadest inclusion criteria and both included patients with
intermediate-risk disease. To date, these studies have demonstrated
low rates of metastases and cancer-related mortality with 50% to
63.5% of patients remaining untreated at 10 years.8,9 Many of these
patients were recruited before the introduction of the International
Society of Urological Pathology modiﬁed Gleason grading sys-
tem in 2005, with studies suggesting that up to one third of Gleason
313 tumors would now be classiﬁed as Gleason 314.10,11 Fur-
thermore, biopsies now increasingly include greater numbers
of cores coupled with multiparametric staging using magnetic
resonance imaging scans, which has led to grade and stage mi-
gration, suggesting that these results reﬂect worst-case scenarios. If
it is demonstrated that very–low-risk versus low-risk patients have
different long-term survival outcomes after AS, this can inform
future clinical practice and guidelines, but until data become
available, we feel that the ASCO endorsement12 with the described
acknowledgment of patient heterogeneity best summarizes cur-
rently available evidence.
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